CAR T-cells for T-cell malignancies challenges in distinguishing between therapeutic, normal, and neoplastic T-cells - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Leukemia Année : 2018

CAR T-cells for T-cell malignancies challenges in distinguishing between therapeutic, normal, and neoplastic T-cells

Résumé

Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrated remarkable efficacy for the treatment of B-cell malignancies. The development of CAR T-cells against T-cell malignancies appears more challenging due to the similarities between the therapeutic, normal and malignant T-cells. The obstacles include CAR T-cell fratricide, T-cell aplasia, and contamination of CAR T-cell products with malignant T-cells. Here, we review these challenges and propose solutions to overcome these limitations.
Fichier principal
Vignette du fichier
Houot_CAR T-cells for T-cell malignancies challenges.pdf (1.33 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-01903063 , version 1 (13-11-2018)

Identifiants

Citer

Marion Alcantara, Melania Tesio, Carl H June, Roch Houot. CAR T-cells for T-cell malignancies challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia, 2018, 32 (11), pp.2307-2315. ⟨10.1038/s41375-018-0285-8⟩. ⟨hal-01903063⟩
410 Consultations
487 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More